TrialBritish journal of clinical pharmacology2014

The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

Ahmed A Othman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.